title: Reversin increase the plasticity of bone marrow-derived mesenchymal stem cell for generation of cardiomyocyte in vitro.
abstract: OBJECTIVE
  to speed up transdifferentiation of bone marrow-derived stem cells into cardiomyocyte in vitro by inducing dedifferentiation of bone marrow-derived mesenchymal stem cell, before induction by 5-aza-2'-deoxycytidine into cardiomyocyte.
  
  
  METHODS
  two-three months old 2.5 kg weight adult male New Zealanad Rabbits were anesthezied with ether, thigh bones were excised, and bone marrow cells were obtained by aspiration.
  
  
  RESULTS
  in our experiments after 1 week of mesenchymal stem cell cultures, 20 nM reversin was given to induce dediferentiation and after 24 hours exposure with 9μM 5-aza-2-deoxycytidine, early phase of cardiomyocyte differentiation appeared as cultured cell were strongly positive for GATA-4 and weakly positive for MLC-2ά, although beating cardiomyocyte has not yet appeared at the end of experiment. These experiments also showed a marked CD34+ and c-kit+ gene expression on RT-PCR examination.
  
  
  CONCLUSIONS
  reversine increase plasticity of bone marrow-derived mesenchymal stem cell to generate cardiomyocyte after 5-aza-2'-deoxycytidine induction. CD34+ and c-kit+ may be a marker for cardiomyocyte progenitor cells.
authors.affiliation: Department of Cardiology and Vascular Medicine, Airlangga University, Surabaya, Indonesia. bsp49@fk.unair.ac.id
authors.forename: Budi S
authors.initials: BS
authors.lastname: Pikir
authors.forename: Helen
authors.initials: H
authors.lastname: Susilowati
authors.forename: Eryk
authors.initials: E
authors.lastname: Hendrianto
authors.forename: Fedik
authors.initials: F
authors.lastname: Abdulrantam
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D015415:Biomarkers / Q000378:metabolism; D001854:Bone Marrow Cells / Q000187:drug effects*; D024722:Cardiac Myosins / Q000378:metabolism; D054337:Cell Dedifferentiation / Q000187:drug effects*; D054338:Cell Transdifferentiation / Q000187:drug effects*; D002478:Cells, Cultured; D000077209:Decitabine; D050991:GATA4 Transcription Factor; D008297:Male; D059630:Mesenchymal Stem Cells / Q000187:drug effects*; D009025:Morpholines / Q000494:pharmacology*; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D018994:Myosin Light Chains / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011687:Purines / Q000494:pharmacology*; D011817:Rabbits; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D018952:Antigens, CD34; D015415:Biomarkers; D050991:GATA4 Transcription Factor; D009025:Morpholines; D018994:Myosin Light Chains; D011687:Purines; C107184:myosin light chain 2; D000077209:Decitabine; D019009:Proto-Oncogene Proteins c-kit; D024722:Cardiac Myosins; D001374:Azacitidine; C484369:2-(4-morpholinoanilino)-6-cyclohexylaminopurine